Faculty Disclosure

In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

Nature of Relevant Financial Relationship Last Name Commercial Interest What Was Received For What Role

 Gilead Sciences, Inc. , Neopharm Labs  Honorarium  Speakers Bureau Box  Alexion Pharmaceuticals, Inc. , Dova  Consulting Fee  Advisory Board Pharmaceuticals  AbbVie, Bayer HealthCare,  Advisory Board Pharmaceuticals, , Merck, Salix  Honorarium Consultant, Research, Pharmaceuticals Speakers Bureau  Advisory Board,  Gilead Sciences, Inc.  Honorarium Consultant, Speakers Bureau  AbbVie, Bristol‐Myers Squibb, Conatus Frenette Pharmaceuticals, Merck, Salix  Honorarium  Speakers Bureau Pharmaceuticals,  Dova Pharmaceuticals, Intercept  Advisory Board,  Honorarium Pharmaceuticals Speakers Bureau  GENFIT, Mallinckrodt  Honorarium  Research Support  Gilead Sciences, Inc., Intercept  Honorarium  Advisory Board Pharmaceutical, Wako Diagnostics  Abbot Laboratories, AbbVie, Alexion Pharmaceuticals , Arrowhead Pharmaceuticals, Bayer Pharmaceuticals, Bristol‐Myers Squibb, Contravir Pharmaceuticals, Eiger Biopharmaceuticals, Enyo  Honorarium  Advisory Board, Pharmaceuticals, eStudySite, Genentech, Consultant Gilead Sciences,Inc., HepaTX, HepQuant, Hoffmann‐LaRoche Ltd., Intellia Therapeutics, Intercept Pharmaceuticals, Ionis Pharmaceuticals, Janssen, MedImmune, Merck, Shionogi Transgene, Trimaran Gish  AbbVie, Arrowhead, Bayer Pharmaceuticals, Contravir Pharmaceuticals, Dova Pharmaceuticals,  Scientific or Clinical Eiger Biopharmaceuticals , Enyo Pharma,  Honorarium Advisory Boards Intercept Pharmaceuticals, Janssen, Medimmune, Merck, Shionogi, Spring Bank  AbbVie, Alexion Pharmaceuticals, Bayer, Bristol‐Myers Squibb, Gilead Sciences Inc.,  Honorarium  Speakers Bureau Merck  Minor Stock  BioPharma, RiboSciences LLC, Synageva,  Stock Shareholder, Stock Triac Options  AbbVie, Bristol‐Myers Squibb, Conatus Kwo  Honorarium  Advisory Board Pharmaceuticals , Dova Pharmaceuticals,

Ferring Pharmaceuticals, Gilead Sciences Inc., Merck, Shiongi,  Assembly Biosciences, Aurora Pharmaceutical, Bristol‐Myers Squibb Gilead Sciences Inc., La Jolla  Grant  Research Pharmaceutical Company, TARGET PharmaSolutions, Trio Pharmaceuticals Inc.  Durect Corporation, Janssen  Data safety and  Honorarium Pharmaceuticals management board

 Durect Corporation  Stock Options  Consultant

 Cara Therapeutics, Target  Honorarium  Consultant Pharmaceutical Solutions  CymaBay Therapeutics, Durect Pharmaceuticals, Enanta Pharmaceuticals, Genfit, Genkyotex Gilead Pharmaceuticals , Glaxo Smith  Research grant  Principle Investigator Levy Kline , HighTide, Intercept Pharmaceuticals, Novartis Pharmaceuticals  Editorial Board  Liver Transplantation Journal  Honorarium Membership

 UpToDate  Royalty  Review panel

 AbbVie  Grant  Principle Investigator Lucey  Pharma Solutions  Grant  Principle Investigator  Consultant, Research,  Gilead Sciences, Inc.  Grant, Honorarium Speakers Bureau Pockros  Cepheid  Grant  Research  Consultant, Research,  AbbVie Gilead Sciences, Inc. , Merck,  Grant, Honorarium Speakers Bureau  Speakers Bureau,  AbbVie, Merck  Honorarium Ramers consultant  Merck  Honorarium  Speakers Bureau

 Clinton Health Access Initiative  Salary  Consultant  Dova Pharmaceuticals, Gilead Sciences,  Honorarium  Advisory Board Inc., Intercept Pharmaceuticals Rosenkoetter  Salix Pharmaceuticals  Honorarium  Speakers Bureau  AbbVie, Gilead Sciences, Inc., Intercept  Honorarium  Speakers Bureau Pharmaceuticals Sussman  Allergan, Wilson Therapeutics  Research  Clinical Trial

 Alexion  Consulting fee  Advisory Board Thomason  Conatus Pharmaceuticals  Honorarium  Principal Investigator  Bristol‐Myers Squibb, Gilead Sciences, Younossi Inc., Intercept Pharmaceutical, Novo  Honorarium  Speakers Bureau Nordisk, Novartis Pharmaceuticals,

Shionogi, Terns Pharmaceuticals Viking Therapeutics, CME Review  None  N/A  N/A Committee Scripps Conference  None  N/A  N/A Services & CME

Glossary of Terms

Commercial Interest The ACCME defines a “commercial interest” as any entity producing, marketing, re‐selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.

Financial Relationships Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Relevant Financial Relationships ACCME focuses on financial relationships with commercial interests in the 12‐month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

Conflict of Interest Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.